Skip to main content

Table 5 Multivariate analysis in neoadjuvantly treated patients with gastric cancer including AEG II, III (UICC 6th)

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

   HR 95% CI p
pT pT0 1.00   0.002
  pT1 2.16 0.2-20.8  
  pT2 5.10 0.7-37.5  
  pT3 9.80 1.3-74.3  
  pT4 14.50 1.7-122.9  
R R0 1.00   0.001
  R1/2 2.20 1.3-3.5  
Clinical response yes 1.00   0.026
  no 2.10 1.1-4.2  
MTHFR A1298C AA 1.00   0.01
  AC 2.00 1.3-3.2  
  CC 1.49 0.7-3.3